CoorsTek Bioceramics has secured another legal victory in its longstanding dispute with CeramTec GmbH over trademark rights to the color pink for ceramic hip components. In the latest ruling, the German Federal Patent Court (GFPC) upheld the cancellation of CeramTec's trademark in Germany, finding that the application had been filed in bad faith with the intention to extend an expiring patent monopoly and keep competitors out of the market. The decision, announced on November 5, 2026, follows similar favorable rulings in France and the United States, strengthening CoorsTek's position in the global orthopaedic ceramics market.
The GFPC's ruling is significant because it addresses a strategic use of trademark law to maintain market exclusivity after a patent expires. By filing for a trademark on the color pink for ceramic hip components, CeramTec sought to extend its monopoly beyond the life of its patent, potentially blocking competitors from using a color that has become associated with ceramic hip implants. The court's finding of bad faith sends a clear signal that such tactics will not be tolerated in Germany. For CoorsTek Bioceramics, the ruling bolsters its ability to market its ceramic hip replacement components, including Permallon orthopaedic ceramics, in Germany and beyond. The company has cited continued court wins and OEM regulatory clearances as building a more competitive orthopaedic ceramics supply chain.
The implications for the medical device industry are substantial. Greater competition in the orthopaedic ceramics market could lead to more choices for implant manufacturers and potentially lower costs. CoorsTek Bioceramics, a wholly owned subsidiary of CoorsTek, Inc., has sold over six million components for clinical use since 2005 and is backed by more than 110 years of technical ceramics expertise. The company focuses on ceramic bearing surfaces for total joint arthroplasty, as well as components for neurological, cardiological, spinal, and radiation applications. With this ruling, CoorsTek can more freely promote its Permallon orthopaedic ceramics, which are designed for hip replacement procedures. The decision also reinforces the importance of intellectual property laws that prevent anti-competitive practices, ensuring that innovation and competition can thrive in the medical device sector.
CeramTec has appealed the decision, so the legal battle may continue. However, CoorsTek's string of victories in multiple jurisdictions suggests a growing consensus that CeramTec's trademark claims were improper. For readers, this news matters because it affects the availability and cost of orthopaedic implants, which are critical for an aging population. A more competitive supply chain can drive innovation and improve patient outcomes. CoorsTek's win is a step toward a fairer marketplace for ceramic hip components. For the full announcement, including downloadable images, bios, and more, click here. The source of this announcement is CoorsTek.
